Viz.ai has announced a proposed collaboration with Guardant Health aimed at transforming lung cancer care through the integration of AI and genomic insights. The partnership seeks to address key challenges in early lung cancer detection and treatment by leveraging cutting-edge technologies to help oncologists make faster, more informed decisions. The goal is to improve patient outcomes by streamlining the patient journey, ensuring that individuals receive timely and personalized care based on real-time insights derived from advanced AI algorithms and genomic data. This collaboration reflects both companies’ shared commitment to using technology to close critical gaps in cancer care.
Lung cancer patients often face delays in diagnosis and treatment, leading to lower survival rates, with nearly 40% not receiving guideline-directed medical therapy. The collaboration between Viz.ai and Guardant Health is designed to bridge these gaps by facilitating earlier biomarker testing with the Guardant360 CDx liquid biopsy. This will speed up the process of precision diagnosis and treatment selection. Viz.ai’s platform, already active in over 1,700 hospitals, uses machine learning to deliver real-time, actionable insights, accelerating diagnoses and directing patients to the appropriate specialists. Together, these innovations aim to optimize the lung cancer care pathway and ultimately improve patient outcomes.
